MDACC Study No:2010-0856 ( NCT No: NCT01294735)
Title:A Phase I Study of MK-4827 in Combination with Temozolomide
in Patients with Advanced Cancer
Principal Investigator:Aung Naing
Treatment Agent:MK-4827; Temozolomide
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of the combination of MK-4827 and temozolomide that can be given to patients
with advanced solid cancers. The effects of the study drugs at different dose
levels and the safety of the study drugs will also be studied.

You are also being asked to take part in optional procedures, which are
described in a separate consent form.
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers
Phase of Study:Phase I
Treatment Agents:MK-4827
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Merck & Co, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Aung Naing
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-563-1930
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults